Skip to the main content.


Brett Kaplan

Managing Director

Brett Kaplan is a Managing Director in the firm’s corporate advisory business.

Mr. Kaplan advised Bristol-Myers on its acquisition of Amylin, Terumo on its acquisition of CaridianBCT, and Fenwal on its sale to Fresenius SE, and Axovant and Novocure on their IPO.

Prior to joining Evercore, Mr. Kaplan was a Large Cap Pharmaceuticals equity research analyst at Cowen and Company. Previously, he was a Director in the corporate development group of Cubist Pharmaceuticals and a Manager in business and clinical development with Biopure Corporation. Mr. Kaplan also spent time at Eli Lilly, South Africa as a Manager of business development and corporate strategy.

Mr. Kaplan received an M.B.A. and MBBCh from the University of the Witwatersrand, South Africa.

< Back to Team

Clients First,


Intern, Analyst and Associate Positions

Evercore's robust programs for undergraduate and graduate students offer career opportunities we believe are unmatched in the industry, including training, mentorship activities, and hands-on transaction experience...
more >

Experienced Hires

Evercore's rapid global expansion and growing industry sector coverage requires that we consistently seek and hire exceptionally-talented senior executives to join our team...
more >